PURPOSE: This study was to investigate the impact of ranibizumab on the level of @entity2071 ( @entity2071 ) in the vitreous of eyes with @entity1106 . METHODS: This is an interventional case-control study. A total of 82 eyes from 82 @entity1 who had undergone vitreous surgery for the treatment of @entity989 were included. Twenty-two eyes with @entity1106 received an @entity3853 ( @entity3853 ) 3-7  days before vitrectomy and were grouped as ' @entity1106 with recent @entity3853 ' or Group 1. Sixteen eyes with @entity1106 received @entity3853 more than 7  days before vitrectomy and were grouped as ' @entity1106 with remote @entity3853 ' or Group 2. Twenty-two matched @entity1106 eyes did not receive @entity3853 before vitrectomy and were grouped as ' @entity1106 without @entity3853 ' or Group 3. Finally, 22 eyes from 22 @entity1 with idiopathic @entity1020 (IMP) served as the 'non-diabetic control' group, or Group 4. Vitreous samples were obtained at the time of vitrectomy from all eyes, and the levels of @entity7 ( @entity7 ) and @entity2071 were analysed using ELISA. RESULTS: @entity1106 without @entity3853 (Group 3) had the highest vitreous @entity7 concentration; the difference was significant compared with those in the @entity1106 with recent @entity3853 (Group 1), @entity1106 with remote @entity3853 (Group 2) and the non-diabetic control group (Group 4) (p  <  0.001). Group 2 had a lower vitreous @entity7 level than Group 1 (p  =  0.041). Group 1 had the highest vitreous @entity2071 levels (p  <  0.001 versus. Groups 2, 3 and 4); Group 2 had a lower vitreous @entity2071 level than Group 3 (p  =  0.028). CONCLUSION: The vitreous fluid level of @entity2071 was significantly increased within 1  week of @entity3853 administration, but markedly decreased after a week of administration in eyes with @entity1106 . This suggests that leucostasis, @entity455 and @entity409 may be amplified in the early days after @entity3853 , but that a therapeutic effect of @entity3853 in these processes may appear after 1  week of ranibizumab administration in eyes with @entity1106 .

The impact of ranibizumab on the level of  XXXX in the vitreous  of  eyes with proliferative diabetic retinopathy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3853 :: ('MESH:C536369', 'Disease') :: ['intravitreal ranibizumab injection', 'IVR'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular leakage'] @entity1106 :: ('MESH:C564461', 'Disease') :: ['PDR'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelium growth factor', 'VEGF'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinal disorders'] @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule type 1'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular pucker']
@entity2071 :: (3383,Gene) :: ['intercellular adhesion molecule type 1']
